FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
Executive Summary
Quantitative measures to evaluate drug risks and benefits would provide FDA a stronger defense against critiques of regulatory decisions, several agency observers suggested
You may also be interested in...
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
Innovative Drug Development Demands Clearer Regulatory Pathways From FDA
Speeding development of innovative therapies requires FDA to more clearly define regulatory pathways for novel drugs, former Abbott Pharma President & COO Jeffrey Leiden said